Aurora Cannabis Starts Shipping Softgel Capsules for Canadian Market

Aurora Cannabis (NYSE:ACB, TSX:ACB) started shipping its cannabis softgel capsules for the Canadian medical and adult-use marijuana markets.

As quoted in the press release:

Aurora expects to commence exports to international markets in early 2019.

At scale, the Company anticipates that softgel production at its state-of-the-art Aurora Vie facility in Quebec will reach at least 1.4 million capsules per week. Aurora intends to make this high-volume, high-margin, smoke-free, product available to all of its domestic and international target markets over time where legally possible.

Aurora’s softgel capsules are produced to pharmaceutical-grade standards at Aurora Vie, in collaboration with leading softgel manufacturer Capcium Inc. (“Capcium”), in which Aurora holds a 19.99 [percent] ownership interest. The Company will initially launch the capsules to the medical cannabis market in Canada as well as the adult-use market in British Columbia with additional provincial markets to follow.

“Softgels are a high-volume, high-margin product for both the medical and adult-use markets that are in strong demand, and Aurora is one of few companies making these products available to patients and consumers alike,” said Terry Booth, CEO of Aurora. “There is a strong momentum towards smoke-free, consistent dosage delivery technologies, and our softgels are a very familiar form factor that satisfy patient and consumer needs. We are delighted to have a preferred partnership with Capcium, whose technology is performing above our initial expectations, delivering high volumes of pharma-grade products.”

Click here to read the full press release.

Source: www.newswire.ca